Labgenomics Co

Labgenomics Co Retained Earnings

The Retained Earnings of Labgenomics Co (084650.KQ) as of Nov 7, 2026 is 82.24 B KRW. In the previous year, Retained Earnings was 146.62 B KRW — a change of -43.91% (lower).

Retained Earnings

82.24 BKRW

YoY

-43.91%

Last updated:

Retained Earnings of Labgenomics Co is 2025 82.24 B KRW. Retained Earnings of Labgenomics Co was 2024 146.62 B KRW. It decreases by -43.91% lower compared to the previous year.

The Labgenomics Co Retained Earnings history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Retained Earnings
Date
Retained Earnings
Jan 1, 2018
3.09 B KRW
Jan 1, 2019
4.25 B KRW
Jan 1, 2020
46.88 B KRW
Jan 1, 2021
129.74 B KRW
Jan 1, 2022
175.23 B KRW
Jan 1, 2023
170.24 B KRW
Jan 1, 2024
146.62 B KRW
Jan 1, 2025
82.24 B KRW
The Labgenomics Co Retained Earnings history
YEARRetained EarningsYoY
82.24 BKRW-43.91%
146.62 BKRW-13.88%
170.24 BKRW-2.84%
175.23 BKRW+35.06%
129.74 BKRW+176.75%
46.88 BKRW+1,002.67%
4.25 BKRW+37.71%
3.09 BKRW-59.03%
7.54 BKRW-31.10%
10.94 BKRW+7.94%
10.13 BKRW+22.17%
8.29 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Labgenomics Co Stock analysis

What does Labgenomics Co do? LabGenomics Co., Ltd. generates revenue through the provision of in vitro diagnostic (IVD) products and services. The company offers general diagnostic check services, molecular diagnostic check services, and research and development services, alongside IVD products such as DNA chips and PCR kits. Its diagnostic services include examinations for breast cancer and colorectal cancer, while its biosensor solutions target point of care testing (POCT). Additionally, LabGenomics sells healthy food as part of its product portfolio. The primary buyers of LabGenomics' services are healthcare institutions requiring diagnostic support, including hospitals and clinics. The company's molecular diagnostic services and cancer examinations are particularly sought after by medical facilities focused on specialized testing. Healthcare providers also purchase its biosensor solutions for immediate testing at the point of care. LabGenomics' product segments include IVD services, IVD products like DNA chips and PCR kits, cancer examination services, and healthy food. The company's molecular diagnostic services and cancer testing are key revenue drivers, while its biosensor for POCT and healthy food offerings serve complementary market segments. Labgenomics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labgenomics Co stock

Retained Earnings of Labgenomics Co is 82.24 B KRW in 2025.

Retained Earnings of Labgenomics Co changed from 146.62 B KRW to 82.24 B KRW, representing a -43.91% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Retained Earnings Labgenomics Co since 2006 – with annual values, charts, and detailed analysis.

Retained earnings are the cumulative net income kept in the business rather than paid out as dividends. They fund future growth and operations.

Retained Earnings's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Retained Earnings's Labgenomics Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Labgenomics Co

All Key Metrics — Labgenomics Co